LT3 Stock Overview
Develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Axogen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.20 |
| 52 Week High | US$18.50 |
| 52 Week Low | US$5.10 |
| Beta | 0.99 |
| 1 Month Change | -3.37% |
| 3 Month Change | 44.54% |
| 1 Year Change | 79.17% |
| 3 Year Change | 166.67% |
| 5 Year Change | 27.41% |
| Change since IPO | 122.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| LT3 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -1.7% | 1.4% | 2.7% |
| 1Y | 79.2% | -2.8% | 17.0% |
Return vs Industry: LT3 exceeded the German Medical Equipment industry which returned -2.8% over the past year.
Return vs Market: LT3 exceeded the German Market which returned 17% over the past year.
Price Volatility
| LT3 volatility | |
|---|---|
| LT3 Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: LT3's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: LT3's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 427 | n/a | www.axogeninc.com |
Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin.
Axogen, Inc. Fundamentals Summary
| LT3 fundamental statistics | |
|---|---|
| Market cap | €760.37m |
| Earnings (TTM) | -€13.63m |
| Revenue (TTM) | €172.35m |
4.4x
P/S Ratio-55.8x
P/E RatioIs LT3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LT3 income statement (TTM) | |
|---|---|
| Revenue | US$180.86m |
| Cost of Revenue | US$38.43m |
| Gross Profit | US$142.43m |
| Other Expenses | US$156.74m |
| Earnings | -US$14.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | -0.33 |
| Gross Margin | 78.75% |
| Net Profit Margin | -7.91% |
| Debt/Equity Ratio | 50.0% |
How did LT3 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 02:58 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Axogen, Inc. is covered by 17 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |
| William Plovanic | Canaccord Genuity |